Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074498 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
A Phase 1 study, sponsored by TrueBinding.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
NCT05074498 is a Phase 1 study that has completed, run by TrueBinding. The registered enrollment target is 154 participants.
The verdict
NCT05074498, a Phase 1 study, has completed, sponsored by TrueBinding.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
Study Summary
Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be conducted to determine the clinical efficacy of TB006 in participants with mild to severe Alzheimer's Disease.
Interventions
- DRUG Placebo
- DRUG TB006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05074498
The ClinicalTrials.gov registry entry for NCT05074498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TrueBinding, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05074498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05074498 about?
NCT05074498 is a clinical study titled "Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease". Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006 (production of anti-TB006 antibody). Part 2 of this study will be condu...
What is the current status of trial NCT05074498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2021-10-08. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT05074498?
The interventions under investigation include: Placebo (DRUG), TB006 (DRUG).
Who is sponsoring clinical trial NCT05074498?
This trial is sponsored by TrueBinding, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.